Bevacizumab Added to Neoadjuvant Chemotherapy in HER2-Negative Non-Metastatic Breast Cancer

Detalles Bibliográficos
Autores principales: Wan, Guoxing, Cao, Fengjun, Wang, Xuanbin, Sun, Xue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2019
Materias:
Letter To The Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360292/
https://www.ncbi.nlm.nih.gov/pubmed/30719135
http://dx.doi.org/10.7150/jca.29461
_version_ 1783392445287890944
author Wan, Guoxing
Cao, Fengjun
Wang, Xuanbin
Sun, Xue
author_facet Wan, Guoxing
Cao, Fengjun
Wang, Xuanbin
Sun, Xue
author_sort Wan, Guoxing
collection PubMed
description
format Online
Article
Text
id pubmed-6360292
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-63602922019-02-04 Bevacizumab Added to Neoadjuvant Chemotherapy in HER2-Negative Non-Metastatic Breast Cancer Wan, Guoxing Cao, Fengjun Wang, Xuanbin Sun, Xue J Cancer Letter To The Editor Ivyspring International Publisher 2019-01-01 /pmc/articles/PMC6360292/ /pubmed/30719135 http://dx.doi.org/10.7150/jca.29461 Text en © Ivyspring International Publisher This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Letter To The Editor
Wan, Guoxing
Cao, Fengjun
Wang, Xuanbin
Sun, Xue
Bevacizumab Added to Neoadjuvant Chemotherapy in HER2-Negative Non-Metastatic Breast Cancer
title Bevacizumab Added to Neoadjuvant Chemotherapy in HER2-Negative Non-Metastatic Breast Cancer
title_full Bevacizumab Added to Neoadjuvant Chemotherapy in HER2-Negative Non-Metastatic Breast Cancer
title_fullStr Bevacizumab Added to Neoadjuvant Chemotherapy in HER2-Negative Non-Metastatic Breast Cancer
title_full_unstemmed Bevacizumab Added to Neoadjuvant Chemotherapy in HER2-Negative Non-Metastatic Breast Cancer
title_short Bevacizumab Added to Neoadjuvant Chemotherapy in HER2-Negative Non-Metastatic Breast Cancer
title_sort bevacizumab added to neoadjuvant chemotherapy in her2-negative non-metastatic breast cancer
topic Letter To The Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6360292/
https://www.ncbi.nlm.nih.gov/pubmed/30719135
http://dx.doi.org/10.7150/jca.29461
work_keys_str_mv AT wanguoxing bevacizumabaddedtoneoadjuvantchemotherapyinher2negativenonmetastaticbreastcancer
AT caofengjun bevacizumabaddedtoneoadjuvantchemotherapyinher2negativenonmetastaticbreastcancer
AT wangxuanbin bevacizumabaddedtoneoadjuvantchemotherapyinher2negativenonmetastaticbreastcancer
AT sunxue bevacizumabaddedtoneoadjuvantchemotherapyinher2negativenonmetastaticbreastcancer

Ejemplares similares